GlassScriptPhysician profile
Maanasi Samant
NPI 1427463074
$14,204.64
in general payments reported to CMS, 2019-2025
14 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $132 · 2021: $34.90 · 2022: $476 · 2023: $8,152 · 2024: $4,542 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,749 · Food and Beverage: $2,487 · Travel and Lodging: $2,054 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,749.00 |
| Food and Beverage | $2,487.16 |
| Travel and Lodging | $2,053.57 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $6,543.40 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Actelion Pharmaceuticals US, INC. | $4,454.31 | 2019-2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $2,021.77 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $199.69 | 2022-2025 | Winrevair |
| Sandoz INC. | $196.13 | 2023 | Treprostinil |
| La Jolla Pharmaceutical Company | $161.67 | 2023-2024 | Giapreza |
| Boston Scientific Corporation | $156.33 | 2025 | Ekosonic |
| Inari Medical, INC. | $152.55 | 2020-2021 | |
| Baxter Healthcare | $121.81 | 2023 | Floseal |
| Penumbra, INC. | $108.43 | 2023 | Indigo System |
| Takeda Pharmaceuticals U.S.A., INC. | $35.42 | 2025 | Glassia |
| Melinta Therapeutics, LLC | $28.39 | 2025 | Rezzayo |
| Inogen, INC. | $24.74 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maanasi Samant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.